Novartis Says Remibrutinib Tops Teriflunomide in Two Phase III RMS Trials
Novartis reported that remibrutinib cut annualized relapse rates by 35.2% and 31.2% versus teriflunomide in two Phase III RMS trials. It also showed a 29.2% nominal reduction in 6mCDP risk, with no liver safety signal; Novartis plans to seek global regulatory approval.
Novartis AG said its oral BTK inhibitor remibrutinib reduced ARR by 35.2% and 31.2% compared with teriflunomide in two Phase III trials in RMS. The trials also showed a 29.2% nominal reduction in the risk of 6mCDP, with no liver safety signal reported. Novartis plans to seek global regulatory approval.